This week's textile clothing block is weak in the market, and the medical beauty cosmetics sector is stronger than the market. During April 11th to April 15th: 1) Shen Wan Textile Apparel Index fell 3.47%, weaker than Shen Wan A Index 1.07Pct. Among them, Shenwan's clothing home textile index fell 2.61%, weaker than Shen Wan A index 0.20PCT Shen Wan Textile Manufacturing Index fell 3.90%, weak in Shenwan A Index 1.50PCT.2) Shen Wanmei Nursing Index rose by 1.57%, and stronger than Shen Wan A index 3.97pct.

Textile and apparel: 1) Textile: 22Q1 textile and clothing exports have a high historical high, and the external demand is strong. March textile yarn, fabric and product exports were 11.8 billion US dollars, the same increase of 22%, Q1 accumulated exports 36.6 billion US dollars, the same increased by 15%; in March costume and clothing annex exports 10.2 billion US dollars, the same increased by 10.5%, Q1 accumulated exports 35.7 billion US dollars, the same increase of 7%. Q1 spinning exports have a high history of high, and the Single 3 months will increase the growth rate than January-February. It is the continuation of textile manufacturing prosperity of external demand. It is expected that the upstream quarterly reports in the industry chain are still expected. 2) Clothing: Epidemic continued to disturb the retail, and sportswear performance is relatively better. Anta brand Q1 water growth increased by 10% -20% high segment, FILA is the same as the number of units, than Yueffen, the news of the Bird Q1 "lead the costume market, although the second quarter is dual pressure, but the industry is long-term Good trend constant, continue to optimize sportswear high bokeh track.

Cosmetics Medical Beauty: In the March industry continues to differentiate, the faucet Q1 performance growth is determined. In March 22, all brand Tmall + shakes total sales have differentiated differentiation, and the head company is better, and the leader Q1 performance maintains a higher growth with strong determinism. The new regulations continue to promote the standardization of children's cosmetics subdivision, and long-term colorant of cosmetics headers.

Key review this week:

Anta Sports 2022Q1 Operation Data Site Review: Drag from the epidemic 22Q1 operated data slightly lower than expected.

1) Anta:

22Q1 retail sales increased by 10% -20% year-on-20%, and the growth rate was increased. 2) FILA: 22Q1 Retail The number of units increased year-on-year, the growth rate is slower, which is seriously affected by the epidemic. 3) Other brands: 22Q1 retail is 40% -45% year-on-year, and the growth rate is increased. Multi-brand matrix build three major growth curves, plugged in multi-growing growth, strong growth in sports, large space, short-term epidemic disturbance does not change the medium and long-term trend, maintain "buy" rating.

Type 1021 Report and 2022 Report: 21 years of $ 2.72 billion, an increase of 18.1% year-on-year, and the net profit of return is 630 million yuan, a year-on-year increase of 25.2%. 22Q1 revenue was 81 million yuan, an increase of 30.2% year-on-year, and the net profit of return was 21.1 billion yuan, a year-on-year increase of 41.3%. It is optimistic that the company is in a strong brand up phase, raising the profit forecast for 22-24 to 8.1 / 10.1 / 1.23 billion, 22PE only 16 times, maintaining the "buy" rating.

Anke Innovation 2021 Report Review: 21 year, 12.57 billion yuan, a year-on-year increase of 34.5%, and the net profit of return is 980 million yuan, a year-on-year increase of 14.7%. The entire line of products achieve rapid growth, and the rise in raw materials has led to the decline in gross profitability, improve the full-channel sales system, and continuously develop emerging markets. Cross-border e-commerce faucet, has higher brands in overseas markets, technology research and development strength to strengthen product competitiveness, product development is expected to promote performance and then speed up, maintain the "increase" rating.

Stable Medical Top Acquisition Review: It is proposed to use the own funds of 730 million yuan to acquire 55% equity of Longtai Medical. Long Thai medical main income rapidly, the high-end wound dressing industry leads, the acquisition corresponds to the valuation, and the future to acquire all the equity, the acquisition is expected to enrich the company's high-end wound dressing business, forming scale and synergistic effect, maintaining "buy" rating.